[HTML][HTML] Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition
…, S Roy, J Mangana, TP Muniz… - … for ImmunoTherapy of …, 2021 - ncbi.nlm.nih.gov
Background Patients with cancer who are infected with severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) are more likely to develop severe illness and die compared with …
coronavirus 2 (SARS-CoV-2) are more likely to develop severe illness and die compared with …
[HTML][HTML] Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+ anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy
…, SD Saibil, DP Arteaga, TP Muniz… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Original research: Biologic subtypes of melanoma predict survival benefit of combination
anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy - PMC Back …
anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy - PMC Back …
[HTML][HTML] Real world outcomes and hepatotoxicity of infliximab in the treatment of steroid-refractory immune-related adverse events
DV Araujo, TP Muniz, A Yang, S Keshavarzi… - Current …, 2021 - mdpi.com
Background and aims: Current guidelines state that infliximab is contraindicated for the
treatment of immune checkpoint inhibitor-related hepatitis (ir-hepatitis) due to the risk of inducing …
treatment of immune checkpoint inhibitor-related hepatitis (ir-hepatitis) due to the risk of inducing …
[HTML][HTML] Study of enzyme replacement therapy for Gaucher Disease: comparative analysis of clinical and laboratory parameters at diagnosis and after two, five and ten …
AMA Souza, TP Muniz, RM Brito - Revista Brasileira de Hematologia …, 2014 - SciELO Brasil
Objective: To evaluate the impact of enzyme replacement therapy for Gaucher Disease on
clinical and laboratory parameters after two, five and ten years of treatment. Methods: Data …
clinical and laboratory parameters after two, five and ten years of treatment. Methods: Data …
Leveraging personalized circulating tumor DNA (ctDNA) for detection and monitoring of molecular residual disease in high-risk melanoma.
S Genta, DV Araujo, S Keshavarzi, T Pimentel Muniz… - 2022 - ascopubs.org
9579 Background: High-risk melanoma has variable prognosis. Adjuvant immuno- (IO) and
targeted therapy (TT) are approved for stage III-IV resected disease. However, a significant …
targeted therapy (TT) are approved for stage III-IV resected disease. However, a significant …
[HTML][HTML] Retrospective comparison of the efficacy and the toxicity of standard and modified FOLFIRINOX regimens in patients with metastatic pancreatic …
…, MDS Donadio, A Cabral, TP Muniz… - Journal of …, 2018 - ncbi.nlm.nih.gov
Background FOLFIRINOX stands a major breakthrough in the management of metastatic
pancreatic adenocarcinoma (MPA). Nonetheless, significant side-effects have been reported …
pancreatic adenocarcinoma (MPA). Nonetheless, significant side-effects have been reported …
[HTML][HTML] A modified recursive partitioning analysis for predicting overall survival in patients with non-small cell lung cancer and central nervous system metastases
TP Muniz, VHF De Jesus, VAR Sousa… - Journal of thoracic …, 2019 - ncbi.nlm.nih.gov
Background Non-small cell lung cancer (NSCLC) is a major cause of brain metastases.
Nonetheless, patients with central nervous system (CNS) spread are poorly represented in …
Nonetheless, patients with central nervous system (CNS) spread are poorly represented in …
BRAF testing timelines and impact on the starting of systemic treatment.
DP Arteaga, Z Saeed Kamil, T Pimentel Muniz, D Liu… - 2021 - ascopubs.org
e21575 Background: Targeted therapy with BRAF and MEK inhibitors constitute part of the
standard treatment for BRAF V600 mutated melanoma. Timely detection of BRAF mutation is …
standard treatment for BRAF V600 mutated melanoma. Timely detection of BRAF mutation is …
Outcomes of non-treatment naive melanoma patients with central nervous system relapse.
T Pimentel Muniz, H Lone, DP Arteaga, D Gray… - 2021 - ascopubs.org
9557 Background: Melanoma has a high probability of central nervous system (CNS) spread.
Although first line nivolumab and ipilimumab resulted in 56% response rate and 29.2 …
Although first line nivolumab and ipilimumab resulted in 56% response rate and 29.2 …
First-in-class microbial ecosystem therapeutics 4 (MET4) in metastatic solid cancer patients treated with immunotherapy: MET4-IO.
…, AA Heirali, PHH Schneeberger, T Pimentel Muniz… - 2020 - ascopubs.org
3098 Background: Therapeutic augmentation of the intestinal microbiome to improve
immunotherapy outcomes is an active area of investigation. Microbial Ecosystem Therapeutics (…
immunotherapy outcomes is an active area of investigation. Microbial Ecosystem Therapeutics (…